Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
DarioHealth Corp.
DRIO
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $49.4M
$7.28
▲ +7.85%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$5.85 - $17.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 52.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary DarioEngage care management platform with integrated clinical workflows
- FDA-cleared smart connected devices with Bluetooth-enabled ecosystem
- Multi-therapeutic area approach addressing multiple chronic conditions
- Direct-to-consumer and B2B2C distribution channels with payer relationships
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Expansion of digital therapeutics adoption post-pandemic
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Weak
-19.6% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DRIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 11, 2026
MAY 13, 2026
Reported EPS of -$1.25 vs -$1.48 consensus (+15.5% surprise). Revenue of $5.6M vs $5.5M expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+15.5%
Next: Aug 11, 2026
Revenue trend · last 8Q
—
—
—
+17%
-14%
-33%
-31%
-17%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$6.3M
$7.4M
$7.6M
$6.8M
$5.4M
$5.0M
$5.2M
$5.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
147.7%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Stifel · May 14, 2026